Silverfin false false 31/08/2024 31/08/2024 01/09/2023 The principal activity of the Company during the financial year was specialist medical practice activities. Leanne Sarah Edwards 02/08/2019 Richard John Edwards 02/08/2019 12135133 2024-08-31 12135133 bus:Director1 2024-08-31 12135133 bus:Director2 2024-08-31 12135133 2023-08-31 12135133 core:CurrentFinancialInstruments 2024-08-31 12135133 core:CurrentFinancialInstruments 2023-08-31 12135133 2023-09-01 2024-08-31 12135133 bus:Micro-entities 2023-09-01 2024-08-31 12135133 bus:FilletedAccounts 2023-09-01 2024-08-31 12135133 bus:AuditExemptWithAccountantsReport 2023-09-01 2024-08-31 12135133 bus:PrivateLimitedCompanyLtd 2023-09-01 2024-08-31 12135133 bus:Director1 2023-09-01 2024-08-31 12135133 bus:Director2 2023-09-01 2024-08-31 12135133 2022-09-01 2023-08-31 iso4217:GBP xbrli:pure

Company No: 12135133 (England and Wales)

SEVERN NEUROSCIENCES LIMITED

Unaudited Financial Statements
For the financial year ended 31 August 2024
Pages for filing with the registrar

SEVERN NEUROSCIENCES LIMITED

UNAUDITED FINANCIAL STATEMENTS

For the financial year ended 31 August 2024

Contents

SEVERN NEUROSCIENCES LIMITED

BALANCE SHEET

As at 31 August 2024
SEVERN NEUROSCIENCES LIMITED

BALANCE SHEET (continued)

For the financial year ended 31 August 2024
2024 2023
£ £
Fixed assets 33,560 51,275
Current assets 195,718 146,948
Creditors: amounts falling due within one year ( 163,101) ( 123,392)
Net current assets 32,617 23,556
Total assets less current liabilities 66,177 74,831
Accruals and deferred income ( 3,331) ( 3,105)
Net assets 62,846 71,726
Capital and reserves 62,846 71,726

For the financial year ending 31 August 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Severn Neurosciences Limited (registered number: 12135133) were approved and authorised for issue by the Board of Directors on 28 August 2025 and were signed on its behalf by:

Richard John Edwards
Director
SEVERN NEUROSCIENCES LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 August 2024
SEVERN NEUROSCIENCES LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

For the For the financial year ended 31 August 2024

1. Company information

The Company is a private company limited by shares and is incorporated in the United Kingdom and registered in England and Wales (Company no. 12135133). The address of its registered office is 5th Floor 25 King Street, Bristol, BS1 4PB, United Kingdom.

2. Employees

2024 2023
Number Number
Monthly average number of persons employed by the Company during the financial year, including directors 4 3

3. Directors’ benefits: advances, credit and guarantees

Advances

The Directors loan account is repayable on demand and interest is charged on overdrawn balances exceeding £10,000 at the official HMRC rates.

At 1 September 2023, the balance owed by the directors was £51,711. During the year, £1,280 was advanced to the directors, and £312 was repaid by the directors. At 31 August 2024, the balance owed to the directors was £52,679.

At 1 September 2022, the balance owed by the directors was £33,498. During the year, £22,269 was advanced to the directors, and £4,056 was repaid by the directors. At 31 August 2023, the balance owed to the directors was £51,711.